The reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) is extremely inefficient. This is thought to be due to epigenetic modifications that preserve cell identity and resist cell fate change in adult tissues. Dissecting the mechanisms that limit the reprogramming of somatic cells into iPSCs is thus expected to provide insights into the mechanisms that normally establish and maintain cellular identity and whose dysregulation may contribute to disease. In order to uncover new regulators of cell identity, we performed a chromatin-focused RNAi screen during iPSC formation. This led to the identification of all subunits of the chromatin assembly factor-1 (CAF-1) complex as major roadblocks of induced pluripotency. CAF-1 is a histone chaperone responsible for depositing histones H3 and H4 onto chromatin during DNA replication. While CAF-1 was previously shown to be critical for heterochromatin maintenance, DNA repair and early development, a role in cellular reprogramming and postnatal life has not yet been reported. Here, we outline three complementary aims to dissect the molecular mechanisms and functional role CAF-1 plays during cellular reprogramming, tissue homeostasis and cancer. In the first aim, we will explore the cellular consequences of CAF-1 loss on cell fate change. Briefly, we will determine whether CAF-1 depletion enhances cell fate change in multiple contexts including reprogramming of distinct cell types into iPSCs as well as two trans differentiation paradigms. We will further investigate how CAF-1 silencing influences the trajectory of induced pluripotency by analyzing defined intermediate stages of iPSC formation. Given CAF-1's role as a replication-dependent histone chaperone, we will then test the hypotheses that its depletion reduces the minimal number of cell divisions required to attain pluripotency and that it renders iPSC formation a deterministic process. In the second aim, we will elucidate the molecular mechanisms by which CAF-1 resists cell fate change. Specifically, we will test the hypothesis that CAF-1 loss facilitates transcription factor access to target genes by opening up chromatin at regulatory elements. Moreover, we will use targeted and unbiased approaches to define those histone marks and histone variants responsible for the observed phenotype. In the third aim, we will explore CAF-1's role in regulating cell fate changes in vivo. In support of a regulatory function i somatic progenitors, we find that CAF-1 knockdown in immature myeloid cell lines triggers differentiation. We will therefore characterize the consequence of CAF-1 reduction on hematopoiesis using a transgenic RNAi system. We will then extend these studies to mouse models of AML and CML in order to interrogate the role of CAF-1 in stabilizing cell identity in cancer. Collectively, this R01 application will contribute to our understanding of how cell fates are stabilized in different cellular contexts by using CAF-1 as a tool. We expect that results from these studies will improve strategies for the generation of desired cell types for regenerative purposes, and may provide new avenues for cancer therapy.

Public Health Relevance

ARRATIVE We recently identified the histone chaperone CAF-1 in a chromatin-focused RNAi screen for facilitators of induced pluripotent stem cell (iPSC) formation, thus pointing to a previously unanticipated role for this class of histone H3/H4 exchange factors in controlling mammalian cell fate. Here, we propose to dissect the molecular and cellular mechanisms by which CAF-1 stabilizes cell identity during induced pluripotency, tissue homeostasis and cancer. Our work will facilitate the generation of therapeutically relevant cell types and may lead to novel strategies to eliminate malignant cells in cancer.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Project (R01)
Project #
5R01HD058013-10
Application #
9696389
Study Section
Development - 2 Study Section (DEV2)
Program Officer
Ravindranath, Neelakanta
Project Start
2008-06-01
Project End
2021-05-31
Budget Start
2019-06-01
Budget End
2021-05-31
Support Year
10
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02114
Schwarz, Benjamin A; Cetinbas, Murat; Clement, Kendell et al. (2018) Prospective Isolation of Poised iPSC Intermediates Reveals Principles of Cellular Reprogramming. Cell Stem Cell 23:289-305.e5
Di Stefano, Bruno; Ueda, Mai; Sabri, Shan et al. (2018) Reduced MEK inhibition preserves genomic stability in naive human embryonic stem cells. Nat Methods 15:732-740
Bar-Nur, Ori; Gerli, Mattia F M; Di Stefano, Bruno et al. (2018) Direct Reprogramming of Mouse Fibroblasts into Functional Skeletal Muscle Progenitors. Stem Cell Reports 10:1505-1521
Brumbaugh, Justin; Di Stefano, Bruno; Wang, Xiuye et al. (2018) Nudt21 Controls Cell Fate by Connecting Alternative Polyadenylation to Chromatin Signaling. Cell 172:629-631
Brumbaugh, Justin; Di Stefano, Bruno; Wang, Xiuye et al. (2018) Nudt21 Controls Cell Fate by Connecting Alternative Polyadenylation to Chromatin Signaling. Cell 172:106-120.e21
Choi, Jiho; Clement, Kendell; Huebner, Aaron J et al. (2017) DUSP9 Modulates DNA Hypomethylation in Female Mouse Pluripotent Stem Cells. Cell Stem Cell 20:706-719.e7
Choi, Jiho; Huebner, Aaron J; Clement, Kendell et al. (2017) Prolonged Mek1/2 suppression impairs the developmental potential of embryonic stem cells. Nature 548:219-223
Cheloufi, Sihem; Hochedlinger, Konrad (2017) Emerging roles of the histone chaperone CAF-1 in cellular plasticity. Curr Opin Genet Dev 46:83-94
Borkent, Marti; Bennett, Brian D; Lackford, Brad et al. (2016) A Serial shRNA Screen for Roadblocks to Reprogramming Identifies the Protein Modifier SUMO2. Stem Cell Reports 6:704-716
Miyoshi, Norikatsu; Stel, Jente M; Shioda, Keiko et al. (2016) Erasure of DNA methylation, genomic imprints, and epimutations in a primordial germ-cell model derived from mouse pluripotent stem cells. Proc Natl Acad Sci U S A 113:9545-50

Showing the most recent 10 out of 38 publications